Pfizer (PFE) Competitors

$25.79 -0.69 (-2.60%)

As of 01:09 PM Eastern

PFE vs. AMGN, GILD, MRNA, NVAX, and ABBV

Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV). These companies are all part of the "medical" sector.

How does Pfizer compare to Amgen?

Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Amgen presently has a consensus price target of $357.12, indicating a potential upside of 8.44%. Pfizer has a consensus price target of $28.74, indicating a potential upside of 11.42%. Given Pfizer's higher probable upside, analysts plainly believe Pfizer is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
Pfizer	3 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.23

Amgen has a net margin of 20.96% compared to Pfizer's net margin of 11.83%. Amgen's return on equity of 137.41% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Pfizer	11.83%	19.44%	8.41%

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$37.22B	4.77	$7.71B	$14.37	22.92
Pfizer	$62.58B	2.35	$7.77B	$1.31	19.69

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.1%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.7%. Amgen pays out 70.1% of its earnings in the form of a dividend. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years and Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.

In the previous week, Pfizer had 27 more articles in the media than Amgen. MarketBeat recorded 85 mentions for Pfizer and 58 mentions for Amgen. Amgen's average media sentiment score of 0.93 beat Pfizer's score of 0.83 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	34 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	45 Very Positive mention(s)	8 Positive mention(s)	17 Neutral mention(s)	7 Negative mention(s)	4 Very Negative mention(s)	Positive

76.5% of Amgen shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 0.6% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Amgen beats Pfizer on 14 of the 20 factors compared between the two stocks.

How does Pfizer compare to Gilead Sciences?

Pfizer (NYSE:PFE) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Gilead Sciences has lower revenue, but higher earnings than Pfizer. Gilead Sciences is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.35	$7.77B	$1.31	19.69
Gilead Sciences	$29.44B	5.50	$8.51B	$6.77	19.28

Pfizer has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Gilead Sciences has a net margin of 28.90% compared to Pfizer's net margin of 11.83%. Gilead Sciences' return on equity of 49.46% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Gilead Sciences	28.90%	49.46%	17.81%

Pfizer presently has a consensus price target of $28.74, indicating a potential upside of 11.42%. Gilead Sciences has a consensus price target of $157.31, indicating a potential upside of 20.55%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.23
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Pfizer had 19 more articles in the media than Gilead Sciences. MarketBeat recorded 85 mentions for Pfizer and 66 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.98 beat Pfizer's score of 0.83 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	45 Very Positive mention(s)	8 Positive mention(s)	17 Neutral mention(s)	7 Negative mention(s)	4 Very Negative mention(s)	Positive
Gilead Sciences	35 Very Positive mention(s)	9 Positive mention(s)	9 Neutral mention(s)	7 Negative mention(s)	2 Very Negative mention(s)	Positive

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.7%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 48.4% of its earnings in the form of a dividend. Pfizer has raised its dividend for 16 consecutive years and Gilead Sciences has raised its dividend for 10 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Gilead Sciences beats Pfizer on 12 of the 20 factors compared between the two stocks.

How does Pfizer compare to Moderna?

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Pfizer has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.35	$7.77B	$1.31	19.69
Moderna	$1.94B	11.33	-$2.82B	-$8.15	N/A

Pfizer has a net margin of 11.83% compared to Moderna's net margin of -143.55%. Pfizer's return on equity of 19.44% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Moderna	-143.55%	-26.64%	-19.32%

Pfizer has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

In the previous week, Pfizer had 34 more articles in the media than Moderna. MarketBeat recorded 85 mentions for Pfizer and 51 mentions for Moderna. Pfizer's average media sentiment score of 0.83 beat Moderna's score of 0.23 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	45 Very Positive mention(s)	8 Positive mention(s)	17 Neutral mention(s)	7 Negative mention(s)	4 Very Negative mention(s)	Positive
Moderna	20 Very Positive mention(s)	9 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	3 Very Negative mention(s)	Neutral

Pfizer presently has a consensus price target of $28.74, indicating a potential upside of 11.42%. Moderna has a consensus price target of $35.73, indicating a potential downside of 35.61%. Given Pfizer's stronger consensus rating and higher possible upside, equities analysts clearly believe Pfizer is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.23
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

68.4% of Pfizer shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Pfizer beats Moderna on 13 of the 17 factors compared between the two stocks.

How does Pfizer compare to Novavax?

Novavax (NASDAQ:NVAX) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.53	$440.30M	$2.41	4.33
Pfizer	$62.58B	2.35	$7.77B	$1.31	19.69

53.0% of Novavax shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 1.0% of Novavax shares are held by insiders. Comparatively, 0.6% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Novavax has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Pfizer has a net margin of 11.83% compared to Novavax's net margin of -14.73%. Pfizer's return on equity of 19.44% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-17.64%	1.18%
Pfizer	11.83%	19.44%	8.41%

In the previous week, Pfizer had 53 more articles in the media than Novavax. MarketBeat recorded 85 mentions for Pfizer and 32 mentions for Novavax. Pfizer's average media sentiment score of 0.83 beat Novavax's score of 0.65 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	11 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	45 Very Positive mention(s)	8 Positive mention(s)	17 Neutral mention(s)	7 Negative mention(s)	4 Very Negative mention(s)	Positive

Novavax presently has a consensus target price of $12.13, suggesting a potential upside of 16.16%. Pfizer has a consensus target price of $28.74, suggesting a potential upside of 11.42%. Given Novavax's higher possible upside, research analysts plainly believe Novavax is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Pfizer	3 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.23

Summary

Pfizer beats Novavax on 13 of the 17 factors compared between the two stocks.

How does Pfizer compare to AbbVie?

Pfizer (NYSE:PFE) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.7%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.4%. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years and AbbVie has raised its dividend for 53 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

Pfizer has a net margin of 11.83% compared to AbbVie's net margin of 5.79%. Pfizer's return on equity of 19.44% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
AbbVie	5.79%	-911.57%	13.43%

In the previous week, Pfizer had 26 more articles in the media than AbbVie. MarketBeat recorded 85 mentions for Pfizer and 59 mentions for AbbVie. AbbVie's average media sentiment score of 1.10 beat Pfizer's score of 0.83 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	45 Very Positive mention(s)	8 Positive mention(s)	17 Neutral mention(s)	7 Negative mention(s)	4 Very Negative mention(s)	Positive
AbbVie	39 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Pfizer has higher earnings, but lower revenue than AbbVie. Pfizer is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.35	$7.77B	$1.31	19.69
AbbVie	$62.82B	5.65	$4.23B	$2.03	98.82

Pfizer presently has a consensus target price of $28.74, suggesting a potential upside of 11.42%. AbbVie has a consensus target price of $252.90, suggesting a potential upside of 26.07%. Given AbbVie's stronger consensus rating and higher probable upside, analysts plainly believe AbbVie is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.23
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Summary

AbbVie beats Pfizer on 12 of the 20 factors compared between the two stocks.

Get Pfizer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFE vs. The Competition

Export

Metric	Pfizer	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$147.13B	$287.59B	$6.19B	$22.85B
Dividend Yield	6.48%	2.79%	2.78%	4.01%
P/E Ratio	19.71	25.70	28.68	28.30
Price / Sales	2.35	4.74	534.15	23.59
Price / Cash	6.03	12.58	43.30	25.49
Price / Book	1.63	6.82	9.97	4.66
Net Income	$7.77B	$11.61B	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-0.67%
1 Month Performance	-6.12%	-2.90%	4.50%	4.28%
1 Year Performance	12.30%	21.24%	40.23%	28.73%

Pfizer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFE Pfizer	4.104 of 5 stars	$25.79 -2.6%	$28.74 +11.4%	+16.2%	$147.13B	$62.58B	19.71	75,000	Trending News Earnings Report Analyst Upgrade Options Volume Analyst Revision
AMGN Amgen	4.601 of 5 stars	$323.85 -1.8%	$357.12 +10.3%	+19.2%	$178.00B	$37.22B	22.54	31,500	Analyst Forecast Insider Trade Analyst Revision
GILD Gilead Sciences	4.861 of 5 stars	$132.69 +0.8%	$157.35 +18.6%	+35.6%	$163.41B	$29.44B	19.60	17,000	Trending News Earnings Report Dividend Announcement Analyst Forecast Gap Down
MRNA Moderna	1.1878 of 5 stars	$47.30 +4.3%	$35.73 -24.5%	+101.7%	$17.92B	$1.94B	N/A	4,700	Trending News Earnings Report Options Volume Analyst Revision
NVAX Novavax	2.0651 of 5 stars	$8.03 -0.1%	$11.88 +47.9%	+55.1%	$1.32B	$1.12B	3.33	1,990	Trending News Earnings Report Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PFE) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Competitors